Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on the Annual General Meeting of Shareholders held on June 24, 2019. Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, filed this report to disclose the approval of ten resolutions by its shareholders.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and shareholder approvals rather than financial performance data.
Material Changes
Significant corporate governance changes were approved, including:
- Appointment of Kesselman & Kesselman as auditors for 2019.
- Re-election of Dror Ben-Asher and Kenneth Reed to the Board of Directors for three-year terms.
- Election of Alla Felder to the Board of Directors for a three-year term.
- Amendments to the Articles of Association to add Preferred Shares and modify the staggered board structure.
- Amendments to the Compensation Policy.
Outlook, Risks, and Unusual Items
The filing details the approval of equity-based compensation plans, including option grants to non-executive directors, the Chairman/CEO (Dror Ben-Asher), and the Chief Operating Officer (Rick Scruggs). No specific forward-looking guidance, risk factors, or unusual items were disclosed in this text.
Key Facts for Investor Verification
- Verify the impact of the new Preferred Shares on existing shareholder dilution.
- Confirm the details of the amended staggered board structure and its effect on corporate control.
- Review the specific terms of the option grants approved for executive and non-executive directors.
- Check the aggregate compensation paid to auditors for the year ended December 31, 2018, as referenced in the filing.